Sodium hyaluronate composite injection containing lidocaine and preparation process thereof
By combining sodium hyaluronate with lidocaine sustained release microspheres and double network structure gel, the problems of pain and inflammatory response of traditional injections are solved, the comfort and beauty effect of injection is improved, and more lasting beauty effect is achieved. .
Patent Information
- Application Number
- CN202410990040.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-22
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-07-22
AI Technical Summary
Traditional sodium hyaluronate injections have pain during injection and inflammatory responses after injection, limiting their comfort and patient acceptance in clinical applications.
N-hydroxysuccinimide and 1-ethyl-3(3-dimethylaminopropyl) carbodiimide activated sodium hyaluronate and coagulated with lidocaine sustained release microspheres and double network structures. The bonding of the glue and the composite microgel reduces the pain and inflammatory response by modifying the mutual protection of sodium hyaluronate and regenerated silkworm.
It significantly improves the comfort and beauty effect of injection, extends the use time of injection, achieves a longer lasting and comprehensive beauty effect, and improves the effects of skin filling, facial plastic surgery and skin moisturizing treatment.
Smart Images

Figure CN118924946A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of cosmetic injection preparation, and in particular to a sodium hyaluronate composite injection containing lidocaine and a preparation process thereof. Background Art
[0002] Sodium hyaluronate, a naturally occurring high-molecular-weight polysaccharide in the human body, is widely distributed in a variety of tissues, including the skin, joint fluid, and vitreous body. Due to its good biocompatibility, moisturizing properties, and biodegradability, sodium hyaluronate is widely used in medical cosmetology, ophthalmic surgery, and osteoarthritis treatment. In recent years, sodium hyaluronate injections have been increasingly used in skin filling, facial plastic surgery, and skin moisturizing treatments to improve skin appearance and texture and reduce wrinkles. However, traditional sodium hyaluronate injections have some problems during use, such as pain during injection and inflammatory reactions after injection. These problems limit its comfort and patient acceptance in clinical applications.
[0003] Therefore, we proposed a sodium hyaluronate composite injection containing lidocaine and its preparation process, so that it can reduce the pain during injection and the inflammatory response after injection, thereby improving the comfort and patient acceptance in clinical applications. Summary of the invention
[0004] In view of the shortcomings of the prior art, the object of the present invention is to provide a sodium hyaluronate composite injection containing lidocaine and a preparation process thereof.
[0005] A preparation process of a sodium hyaluronate composite injection containing lidocaine comprises the following steps:
[0006] S1: Preparation of modified sodium hyaluronate
[0007] The sodium hyaluronate is activated by N-hydroxysuccinimide and 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide, and then cysteamine hydrochloride is added to react and dialyzed to obtain modified sodium hyaluronate;
[0008] S2: Preparation of lidocaine sustained-release microspheres
[0009] Lidocaine sustained-release microspheres were prepared by loading lidocaine with poly-L-lactic acid and cooperating with chitosan and poloxamer 407.
[0010] S3: Preparation of double network structure gel
[0011] The silk fiber is dialyzed in a lithium bromide solution to prepare a regenerated silk solution, which is then mixed with a modified sodium hyaluronate solution, and horseradish peroxidase and hydrogen peroxide are added to obtain a double network structure gel after incubation.
[0012] S4: Preparation of composite microgel injection
[0013] The double network structure gel is immersed in a phosphate buffer solution to obtain a block hydrogel. The block hydrogel, propylene glycol, tripeptide-1, phytosphingosine and lecithin are mixed and homogenized, and then a composite microgel is prepared by a liquid nitrogen quick freezing-crushing method. The composite microgel is dispersed in a physiological buffer solution and lidocaine sustained-release microspheres are added to obtain a composite microgel injection.
[0014] Furthermore, the preparation of modified sodium hyaluronate in step S1 specifically comprises the following steps:
[0015] S1.1: Dissolve 4-5 parts by weight of sodium hyaluronate powder in 800-1000 parts by weight of deionized water, then add 2-3 parts by weight of N-hydroxysuccinimide and 5-7 parts by weight of 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide in sequence, mix well, adjust the pH to 4-5 with 1.0-1.2 mol / L hydrogen chloride solution, activate at room temperature for 2-3 hours, and obtain an activated solution;
[0016] S1.2: Add 3-4 parts by weight of cysteamine hydrochloride to the activation solution, then adjust the pH to 4-5 with 1.0-1.2 mol / L sodium hydroxide solution, and react at 23-25° C. in the dark for 20-24 hours to obtain a reactant;
[0017] S1.3: Transfer the reactants to a dialysis bag and dialyze with deionized water at a pH of 3.5-4 at 23-25°C in the dark for 3-4 days. Then freeze-dry the dialyzed solution to obtain a modified sodium hyaluronate solid, and store it in a refrigerator at 4-5°C for later use.
[0018] Furthermore, step S2 of preparing lidocaine sustained-release microspheres specifically comprises the following steps:
[0019] S2.1: chitosan and poloxamer 407 are mixed, 1-2 wt% acetic acid is added, the mixture is evenly mixed, and after dissolution, an in-situ gel solution is obtained, and 1-2 parts by weight of lidocaine hydrochloride is added to 10-15 parts by weight of the in-situ gel solution to obtain a mixed solution;
[0020] S2.2: dissolving 0.25-0.5 parts by weight of poly-L-lactic acid in 2-3 parts by weight of dichloromethane to obtain an oil phase after complete dissolution, adding 0.2-0.3 parts by weight of the mixed solution to the oil phase, and mixing for 1-2 minutes under ice bath conditions at 470-500W ultrasonic assistance to obtain a primary emulsion;
[0021] S2.3: adding the primary emulsion to 5-8 parts by weight of a 1-2% (w / v) polyvinyl alcohol solution, stirring for 1-2 min at 3400-3500 rpm using a high-speed disperser to obtain a double emulsion, adding the double emulsion to 60-80 parts by weight of a 0.2-0.5% (w / v) polyvinyl alcohol solution, and magnetically stirring at 37-38° C. for 4-5 h to obtain a solidified microsphere solution;
[0022] S2.4: Centrifuge the solidified microsphere solution at 3500-4000 rpm for 10-12 min, and then wash the precipitate with distilled water 2-3 times to obtain lidocaine sustained-release microspheres.
[0023] Furthermore, step S3 of preparing the double network structure gel specifically comprises the following steps:
[0024] S3.1: 10-20 parts by weight of silk fibroin are placed in 100-200 parts by weight of a 9-10 mol / L lithium bromide solution, stirred and dissolved at 60-62°C for 60-70 min, cooled and placed in a dialysis bag, dialyzed with deionized water for 2-3 days, filtered with absorbent cotton, and centrifuged at 10000-11000 rpm for 5-10 min to obtain a regenerated silk fibroin solution;
[0025] S3.2: dissolving the modified sodium hyaluronate solid in deionized water to form a modified sodium hyaluronate solution with a mass fraction of 1-2%, then adjusting the pH to 7.4-7.6 with a sodium hydroxide solution, and then adding an equal mass of the regenerated silk fibroin solution and mixing in an ice bath to obtain a mixed solution;
[0026] S3.3: Add horseradish peroxidase to the mixed solution, then add hydrogen peroxide, stir evenly, place in a biochemical incubator and incubate at 37-38°C for 3-5 hours to obtain a double network structure gel.
[0027] Furthermore, step S4 of preparing the composite microgel injection specifically comprises the following steps:
[0028] S4.1: Soaking the double network structure gel in a 0.01-0.02 mol / L phosphate buffer solution for 3-4 days to obtain a block hydrogel;
[0029] S4.2: Add 10-20 parts by weight of block hydrogel, 0.2-0.3 parts by weight of propylene glycol and 1-2 parts by weight of tripeptide-1 to 50-80 parts by weight of pure water, and heat in a water bath at 45-48° C. to dissolve to obtain a mixed solution;
[0030] S4.3: Add 1-2 parts by weight of phytosphingosine to 2-3 parts by weight of lecithin, heat in a water bath at 45-48°C to dissolve, add to the mixture, perform ultrasonic dispersion for 10-20 minutes, and homogenize with a microfluidizer to obtain a mixed emulsified gel solution;
[0031] S4.4: The mixed emulsified gel solution was placed in liquid nitrogen for quick freezing for 5-8 minutes, then placed in a mortar, crushed with a pestle and repeatedly ground, and sieved with 400-500 μm and 300-400 μm stainless steel sieves in turn to obtain a composite microgel of 300-500 μm;
[0032] S4.5: The composite microgel is uniformly dispersed in 30-50 parts by weight of physiological buffer, and then 2-3 parts by weight of lidocaine sustained-release microspheres are added, ultrasonically assisted with oscillation for 10-20 minutes, and vacuum-packed after sterilization to obtain a composite microgel injection.
[0033] Furthermore, the concentration of chitosan in the mixed solution of step S2.1 is 3.5-4%.
[0034] Furthermore, the concentration of Poloxamer 407 in the mixed solution of step S2.1 is 2.5-3%.
[0035] Furthermore, the concentration of horseradish peroxidase in the mixed solution of step S3.3 is 10-12 U / mL.
[0036] Furthermore, the concentration of hydrogen peroxide in the mixed solution in step S3.3 is 3-4 mmol / L.
[0037] A sodium hyaluronate composite injection containing lidocaine is prepared by the preparation process of a sodium hyaluronate composite injection containing lidocaine described in any one of the above items.
[0038] Compared with the prior art, the present invention has at least the following beneficial effects:
[0039] 1. The present invention optimizes the formula of the composite injection and adds lidocaine, which can reduce the pain during injection and the inflammatory response after injection, thereby improving the comfort and patient acceptance in clinical applications. At the same time, tripeptide-1 and phytosphingosine active ingredients are added to be compatible with sodium hyaluronate and regenerated silk fibroin. The synergistic effect can not only significantly improve the effects of skin filling, facial plastic surgery and skin moisturizing treatment, but also promote the long-term health and youthfulness of the skin, and achieve a more comprehensive and lasting beauty effect.
[0040] 2. The present invention obtains thiolated modified sodium hyaluronate by thiolation of sodium hyaluronate, and then utilizes the dual mediation effect of horseradish peroxidase on the thiol group on the side chain of modified sodium hyaluronate and the phenolic hydroxyl group on the side chain of regenerated silk fibroin to generate disulfide bonds between the modified sodium hyaluronate macromolecules and dityrosine bonds between the tyrosine residues on the side chains of the regenerated silk fibroin macromolecules, thereby preparing a gel with a double network structure. The double network structure in the gel generates a mutual protection effect on the two components of modified sodium hyaluronate and regenerated silk fibroin fibers, which can basically maintain the original particle morphology. The ability of the double network gel to resist enzyme degradation is significantly enhanced, and the degradation rate is significantly reduced. Therefore, the use effect of the composite injection can be improved to achieve a lasting cosmetic effect.
[0041] 3. The present invention adds chitosan and poloxamer 407 in the preparation of lidocaine sustained-release microspheres. The addition of chitosan and poloxamer 407 greatly improves the drug encapsulation rate and drug loading of the microspheres, effectively improving the anesthetic and analgesic effects. In addition, poly-L-lactic acid is used as an encapsulation material to achieve lidocaine sustained release. At the same time, poly-L-lactic acid can increase the expression of type III collagen, promote skin collagen regeneration, increase the expression of IL-10 and TIMP1, reduce inflammatory response, and regulate the expression of matrix metalloproteinases MMP-2 and MMP-3, thereby reducing the destruction of collagen and elastin fibers in the extracellular matrix of aged skin. Poly-L-lactic acid has a significant promoting effect on fibrous tissue regeneration, thereby improving the cosmetic effect of the composite injection.
[0042] 4. The present invention prepares composite microgels with particle sizes mainly distributed in the range of 300-500 μm through the "liquid nitrogen quick freezing-crushing method". This method has no obvious damage to the pore structure inside the microgel and can maintain a double network structure. The regenerated silk component in the composite microgel and the high internal porosity are more conducive to cell adhesion, spreading and guiding the uniform distribution of cells inside the gel. The composite microgel with a double network structure can provide physical protection for cells, significantly maintain the proliferation vitality of cells, accelerate the regeneration and repair of soft tissues in the body, and improve its filling and cosmetic effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] The accompanying drawings, which are incorporated herein and constitute a part of the specification, illustrate embodiments of the present disclosure and, together with the description, further serve to explain the principles of the present disclosure and to enable those skilled in the relevant art to make and use the present disclosure.
[0044] Figure 1 The present invention is a flow chart of the preparation process of a sodium hyaluronate composite injection containing lidocaine used in an embodiment of the present invention. DETAILED DESCRIPTION
[0045] The following is a detailed description of the preparation process of a sodium hyaluronate composite injection containing lidocaine provided by the present invention in conjunction with the accompanying drawings and specific embodiments. At the same time, it is explained here that in order to make the embodiments more detailed, the following embodiments are the best and preferred embodiments, and those skilled in the art may also adopt other alternatives to implement some known technologies; and the accompanying drawings are only for a more specific description of the embodiments, and are not intended to specifically limit the present invention.
[0046] Example 1
[0047] A preparation process of a sodium hyaluronate composite injection containing lidocaine, such as Figure 1 As shown, the following steps are included:
[0048] S1: Preparation of modified sodium hyaluronate
[0049] S1.1: 4 parts by weight of sodium hyaluronate powder was dissolved in 800 parts by weight of deionized water, and then 2 parts by weight of N-hydroxysuccinimide and 5 parts by weight of 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide were added in sequence. After mixing evenly, the pH was adjusted to 4 with 1.0 mol / L hydrogen chloride solution, and activated at room temperature for 2 hours to obtain an activated solution;
[0050] S1.2: Add 3 parts by weight of cysteamine hydrochloride to the activation solution, then adjust the pH to 4 with 1.0 mol / L sodium hydroxide solution, and react at 23° C. in the dark for 20 h to obtain a reactant;
[0051] S1.3: The reactant was transferred to a dialysis bag, and dialyzed with deionized water at pH 3.5 at 23°C in the dark for 3 days, and then the dialyzed solution was freeze-dried to obtain a modified sodium hyaluronate solid, which was placed in a refrigerator at 4°C for later use;
[0052] S2: Preparation of lidocaine sustained-release microspheres
[0053] S2.1: chitosan and poloxamer 407 are mixed, 1 wt% acetic acid is added, the mixture is evenly mixed, and an in-situ gel solution is obtained after dissolution. 1 part by weight of lidocaine hydrochloride is added to 10 parts by weight of the in-situ gel solution to obtain a mixed solution, wherein the concentration of chitosan in the mixed solution is 3.5%, and the concentration of poloxamer 407 is 2.5%;
[0054] S2.2: 0.25 parts by weight of poly-L-lactic acid was dissolved in 2 parts by weight of dichloromethane to obtain an oil phase after complete dissolution, 0.2 parts by weight of the mixed solution was added to the oil phase, and mixed with ultrasound at 470W for 1 min under ice bath conditions to obtain a primary emulsion;
[0055] S2.3: adding the primary emulsion to 5 parts by weight of a 1% (w / v) polyvinyl alcohol solution, stirring at 3400 rpm for 1 min using a high-speed disperser to obtain a double emulsion, adding the double emulsion to 60 parts by weight of a 0.2% (w / v) polyvinyl alcohol solution, and magnetically stirring at 37° C. for 4 h to obtain a solidified microsphere solution;
[0056] S2.4: centrifuging the solidified microsphere solution at 3500 rpm for 10 min, and then washing the precipitate twice with distilled water to obtain lidocaine sustained-release microspheres;
[0057] S3: Preparation of double network structure gel
[0058] S3.1: 10 parts by weight of silk fiber was placed in 100 parts by weight of 9 mol / L lithium bromide solution, stirred and dissolved at 60°C for 60 min, cooled and placed in a dialysis bag, dialyzed with deionized water for 2 days, filtered with absorbent cotton, and centrifuged at 10000 rpm for 5 min to obtain a regenerated silk solution;
[0059] S3.2: dissolving the modified sodium hyaluronate solid in deionized water to form a modified sodium hyaluronate solution with a mass fraction of 1%, then adjusting the pH to 7.4 with a sodium hydroxide solution, and then adding an equal mass of the regenerated silk fibroin solution and mixing under an ice bath to obtain a mixed solution;
[0060] S3.3: Add horseradish peroxidase to the mixed solution, the concentration of horseradish peroxidase in the mixed solution is 10U / mL, then add hydrogen peroxide to make the concentration of hydrogen peroxide in the mixed solution 3mmol / L, stir evenly, place in a biochemical incubator and incubate at 37°C for 3h to obtain a double network structure gel;
[0061] S4: Preparation of composite microgel injection
[0062] S4.1: Soak the double network structure gel in 0.01 mol / L phosphate buffer solution for 3 days to obtain a block hydrogel;
[0063] S4.2: 10 parts by weight of block hydrogel, 0.2 parts by weight of propylene glycol and 1 part by weight of tripeptide-1 were added to 50 parts by weight of pure water, and heated in a water bath at 45° C. to dissolve to obtain a mixed solution;
[0064] S4.3: Add 1 part by weight of phytosphingosine to 2 parts by weight of lecithin, heat in a water bath at 45°C to dissolve, add to the mixture, perform ultrasonic dispersion for 10 minutes, and homogenize with a microfluidizer to obtain a mixed emulsified gel solution;
[0065] S4.4: The mixed emulsified gel solution was placed in liquid nitrogen and quickly frozen for 5 min, then placed in a mortar, crushed with a pestle and repeatedly ground, and sieved with 400 μm and 300 μm stainless steel sieves in turn to obtain a composite microgel of 300-400 μm;
[0066] S4.5: The composite microgel is uniformly dispersed in 30 parts by weight of physiological buffer, and then 2 parts by weight of lidocaine sustained-release microspheres are added, ultrasonically assisted with oscillation for 10 minutes, and vacuum-packed after sterilization to obtain a composite microgel injection.
[0067] Example 2
[0068] A preparation process of a sodium hyaluronate composite injection containing lidocaine, such as Figure 1 As shown, the following steps are included:
[0069] S1: Preparation of modified sodium hyaluronate
[0070] S1.1: Dissolve 5 parts by weight of sodium hyaluronate powder in 1000 parts by weight of deionized water, then add 3 parts by weight of N-hydroxysuccinimide and 7 parts by weight of 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide in sequence, mix well, adjust the pH to 5 with 1.2 mol / L hydrogen chloride solution, activate at room temperature for 2 hours, and obtain an activated solution;
[0071] S1.2: Add 4 parts by weight of cysteamine hydrochloride to the activation solution, then adjust the pH to 5 with 1.2 mol / L sodium hydroxide solution, and react at 23° C. in the dark for 20 hours to obtain a reactant;
[0072] S1.3: The reactant was transferred to a dialysis bag, and dialyzed with deionized water at pH 4 at 23°C in the dark for 3 days, and then the dialyzed solution was freeze-dried to obtain a modified sodium hyaluronate solid, which was placed in a refrigerator at 4°C for later use;
[0073] S2: Preparation of lidocaine sustained-release microspheres
[0074] S2.1: chitosan and poloxamer 407 are mixed, and then 2 wt% acetic acid is added, and the mixture is uniformly mixed and dissolved to obtain an in-situ gel solution, and 2 parts by weight of lidocaine hydrochloride is added to 15 parts by weight of the in-situ gel solution to obtain a mixed solution, wherein the concentration of chitosan in the mixed solution is 4%, and the concentration of poloxamer 407 is 3%;
[0075] S2.2: 0.5 parts by weight of poly-L-lactic acid was dissolved in 3 parts by weight of dichloromethane to obtain an oil phase after complete dissolution, 0.3 parts by weight of the mixed solution was added to the oil phase, and mixed with ultrasound at 470W for 1 min under ice bath conditions to obtain a primary emulsion;
[0076] S2.3: adding the primary emulsion to 8 parts by weight of a 2% (w / v) polyvinyl alcohol solution, stirring at 3400 rpm for 1 min using a high-speed disperser to obtain a double emulsion, adding the double emulsion to 80 parts by weight of a 0.5% (w / v) polyvinyl alcohol solution, and magnetically stirring at 37° C. for 4 h to obtain a solidified microsphere solution;
[0077] S2.4: centrifuging the solidified microsphere solution at 3500 rpm for 10 min, and then washing the precipitate twice with distilled water to obtain lidocaine sustained-release microspheres;
[0078] S3: Preparation of double network structure gel
[0079] S3.1: 20 parts by weight of silk fiber were placed in 200 parts by weight of 10 mol / L lithium bromide solution, stirred and dissolved at 60°C for 60 min, cooled and placed in a dialysis bag, dialyzed with deionized water for 2 days, filtered with absorbent cotton, and centrifuged at 10000 rpm for 5 min to obtain a regenerated silk solution;
[0080] S3.2: dissolving the modified sodium hyaluronate solid in deionized water to form a modified sodium hyaluronate solution with a mass fraction of 2%, then adjusting the pH to 7.6 with a sodium hydroxide solution, and then adding an equal mass of the regenerated silk fibroin solution and mixing under an ice bath to obtain a mixed solution;
[0081] S3.3: Add horseradish peroxidase to the mixed solution, the concentration of horseradish peroxidase in the mixed solution is 12U / mL, then add hydrogen peroxide to make the concentration of hydrogen peroxide in the mixed solution 4mmol / L, stir evenly, place in a biochemical incubator and incubate at 37°C for 3h to obtain a double network structure gel;
[0082] S4: Preparation of composite microgel injection
[0083] S4.1: Soak the double network structure gel in 0.02 mol / L phosphate buffer solution for 3 days to obtain a block hydrogel;
[0084] S4.2: Add 20 parts by weight of block hydrogel, 0.3 parts by weight of propylene glycol and 2 parts by weight of tripeptide-1 to 80 parts by weight of pure water, and heat in a water bath at 45° C. to dissolve to obtain a mixed solution;
[0085] S4.3: Add 2 parts by weight of phytosphingosine to 3 parts by weight of lecithin, heat in a water bath at 45°C to dissolve, add to the mixture, perform ultrasonic dispersion for 10 minutes, and homogenize with a microfluidizer to obtain a mixed emulsified gel solution;
[0086] S4.4: The mixed emulsified gel solution was placed in liquid nitrogen and quickly frozen for 5 min, then placed in a mortar, crushed with a pestle and repeatedly ground, and sieved with 400 μm and 300 μm stainless steel sieves in turn to obtain a composite microgel of 300-400 μm;
[0087] S4.5: The composite microgel is uniformly dispersed in 50 parts by weight of physiological buffer, and then 3 parts by weight of lidocaine sustained-release microspheres are added, ultrasonically assisted with oscillation for 10 minutes, and vacuum-packed after sterilization to obtain a composite microgel injection.
[0088] Example 3
[0089] A preparation process of a sodium hyaluronate composite injection containing lidocaine, such as Figure 1 As shown, the following steps are included:
[0090] S1: Preparation of modified sodium hyaluronate
[0091] S1.1: 4 parts by weight of sodium hyaluronate powder was dissolved in 800 parts by weight of deionized water, and then 2 parts by weight of N-hydroxysuccinimide and 5 parts by weight of 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide were added in sequence, and after mixing evenly, the pH was adjusted to 4 with 1.0 mol / L hydrogen chloride solution, and activated at room temperature for 3 hours to obtain an activated solution;
[0092] S1.2: Add 3 parts by weight of cysteamine hydrochloride to the activation solution, then adjust the pH to 4 with 1.0 mol / L sodium hydroxide solution, and react at 25° C. in the dark for 24 hours to obtain a reactant;
[0093] S1.3: The reactant was transferred to a dialysis bag, and dialyzed with deionized water at a pH of 3.5 at 25°C in the dark for 4 days, and then the dialyzed solution was freeze-dried to obtain a modified sodium hyaluronate solid, which was placed in a refrigerator at 5°C for later use;
[0094] S2: Preparation of lidocaine sustained-release microspheres
[0095] S2.1: chitosan and poloxamer 407 are mixed, 1 wt% acetic acid is added, the mixture is evenly mixed, and an in-situ gel solution is obtained after dissolution. 1 part by weight of lidocaine hydrochloride is added to 10 parts by weight of the in-situ gel solution to obtain a mixed solution, wherein the concentration of chitosan in the mixed solution is 3.5%, and the concentration of poloxamer 407 is 2.5%;
[0096] S2.2: 0.25 parts by weight of poly-L-lactic acid was dissolved in 2 parts by weight of dichloromethane to obtain an oil phase after complete dissolution, 0.2 parts by weight of the mixed solution was added to the oil phase, and mixed with ultrasound at 500W for 2 minutes under ice bath conditions to obtain a primary emulsion;
[0097] S2.3: adding the primary emulsion to 5 parts by weight of a 1% (w / v) polyvinyl alcohol solution, stirring at 3500 rpm for 2 min using a high-speed disperser to obtain a double emulsion, adding the double emulsion to 60 parts by weight of a 0.2% (w / v) polyvinyl alcohol solution, and magnetically stirring at 38° C. for 5 h to obtain a solidified microsphere solution;
[0098] S2.4: centrifuging the solidified microsphere solution at 4000 rpm for 12 min, and then washing the precipitate with distilled water for 3 times to obtain lidocaine sustained-release microspheres;
[0099] S3: Preparation of double network structure gel
[0100] S3.1: 10 parts by weight of silk fiber were placed in 100 parts by weight of 9 mol / L lithium bromide solution, stirred and dissolved at 62°C for 70 min, cooled and placed in a dialysis bag, dialyzed with deionized water for 3 days, filtered with absorbent cotton, and centrifuged at 11000 rpm for 10 min to obtain a regenerated silk fibroin solution;
[0101] S3.2: dissolving the modified sodium hyaluronate solid in deionized water to form a modified sodium hyaluronate solution with a mass fraction of 1%, then adjusting the pH to 7.4 with a sodium hydroxide solution, and then adding an equal mass of the regenerated silk fibroin solution and mixing under an ice bath to obtain a mixed solution;
[0102] S3.3: Add horseradish peroxidase to the mixed solution, the concentration of horseradish peroxidase in the mixed solution is 10U / mL, then add hydrogen peroxide to make the concentration of hydrogen peroxide in the mixed solution 3mmol / L, stir evenly, place in a biochemical incubator and incubate at 38°C for 5h to obtain a double network structure gel;
[0103] S4: Preparation of composite microgel injection
[0104] S4.1: Soak the double network structure gel in 0.01 mol / L phosphate buffer solution for 4 days to obtain a block hydrogel;
[0105] S4.2: 10 parts by weight of block hydrogel, 0.2 parts by weight of propylene glycol and -2 parts by weight of tripeptide-1 are added to 50 parts by weight of pure water, and heated in a water bath at 48°C to dissolve to obtain a mixed solution;
[0106] S4.3: Add 1 part by weight of phytosphingosine to 2 parts by weight of lecithin, heat in a water bath at 48°C to dissolve, add to the mixture, perform ultrasonic dispersion for 20 minutes, and homogenize with a microfluidizer to obtain a mixed emulsified gel solution;
[0107] S4.4: The mixed emulsified gel solution was placed in liquid nitrogen and quickly frozen for 8 minutes, then placed in a mortar, crushed with a pestle and repeatedly ground, and sieved with 500 μm and 400 μm stainless steel sieves in turn to obtain a composite microgel of 400-500 μm;
[0108] S4.5: The composite microgel is uniformly dispersed in 30 parts by weight of physiological buffer, and then 2 parts by weight of lidocaine sustained-release microspheres are added, ultrasonically assisted with oscillation for 20 minutes, and vacuum-packed after sterilization to obtain a composite microgel injection.
[0109] Comparative Example 1
[0110] Compared with Example 1, the difference of Comparative Example 1 is that Comparative Example 1 removes step S3.3 and step S4.1, replaces the block hydrogel in step S4.2 with an equal weight portion of the mixed solution of step S3.2, and the other steps remain unchanged to prepare a composite microgel injection, which is recorded as Comparative Example 1.
[0111] Comparative Example 2
[0112] Compared with Example 1, the difference of Comparative Example 2 is that Comparative Example 2 removes step S1, step S3.3 and step S4.1, replaces the modified sodium hyaluronate solid in step S3.2 with an equal mass of sodium hyaluronate, and replaces the block hydrogel in step S4.2 with an equal weight of the mixed solution of step S3.2, and the other steps remain unchanged to prepare a composite microgel injection, which is recorded as Comparative Example 2.
[0113] Evaluation of anti-enzymatic performance
[0114] Accurately weigh 0.5 g of the composite microgel injection of Examples 1-3 and Comparative Example 1, add 2 mL of phosphate buffer (0.1 mol / L, pH 7.0) and 2 mL of hyaluronidase solution (600 U / mL), mix well, place in a 42°C water bath, take 50 μL of the mixed solution at different enzymolysis time points and dilute to 3 mL, and measure the absorbance at 232 nm with a Thermo Evolution 201 ultraviolet spectrophotometer. The time when the absorbance no longer changes is the enzymolysis time.
[0115] The measurement results are shown in Table 1.
[0116] Table 1. Results of enzymolysis time determination in Examples 1-3 and Comparative Example 1
[0117] Enzymatic hydrolysis time (h) Example 1 62 Example 2 60 Example 3 61 Comparative Example 1 21 Comparative Example 2 10.5
[0118] It can be seen from the data in Table 1 that the enzymatic hydrolysis time of the embodiment is significantly higher than that of comparative examples 1-2, indicating that the ability of the prepared double network gel to resist enzymatic degradation is significantly enhanced and the degradation rate is significantly reduced. Therefore, the use effect of the composite injection can be improved, so that the composite injection can be retained in the body for a longer time, achieving a lasting cosmetic effect.
[0119] Comparative Example 3
[0120] Compared with Example 1, the difference of Comparative Example 3 is that, in Comparative Example 3, step S2.1 is removed, and the mixed solution in S2.2 is replaced with an equal weight portion of lidocaine hydrochloride, and the other steps remain unchanged to prepare a composite microgel injection, which is recorded as Comparative Example 3.
[0121] The drug loading and encapsulation efficiency of lidocaine sustained-release microspheres of Examples 1-3 and Comparative Example 3 were determined by photometry. The results are shown in Table 2.
[0122] Table 2. Results of drug loading and encapsulation efficiency determination of Examples 1-3 and Comparative Example 3
[0123] Drug loading (%) Encapsulation rate (%) Example 1 23.17 42.34 Example 2 22.89 41.28 Example 3 22.91 41.82 Comparative Example 3 13.68 26.87
[0124] It can be seen from the data in Table 2 that the drug loading and encapsulation efficiency of the embodiment are higher than those of the comparative example, indicating that the addition of chitosan and poloxamer 407 greatly improves the drug encapsulation efficiency and drug loading of the microspheres, effectively improving and prolonging the anesthetic analgesic effect.
[0125] Comparative Example 4
[0126] Compared with Example 1, the difference of Comparative Example 4 is that step S2 is removed in Comparative Example 4, and the lidocaine sustained-release microspheres in step S4.5 are replaced with an equal weight portion of lidocaine hydrochloride, which is recorded as Comparative Example 4.
[0127] Evaluation of collagen secretion content of cells
[0128] Examples 1-3 and Comparative Example 4 were selected to carry out cell culture for 7 days, and the total collagen content was determined using a collagen ELISA kit. The determination results are shown in Table 3.
[0129] Table 3. Collagen content determination results of Examples 1-3 and Comparative Example 4
[0130] Collagen content pg / mL Example 1 39.2 Example 2 38.7 Example 3 38.9 Comparative Example 4 30.4
[0131] It can be seen from the data in Table 3 that the data in the examples are all higher than those in the comparative example 4, indicating that the use of poly-L-lactic acid as an encapsulating material can achieve sustained release of lidocaine while promoting the secretion of autologous collagen, thereby achieving a long-lasting and natural beauty effect.
[0132] The above embodiments are merely illustrative of the principles and effects of the present invention, and are not intended to limit the present invention. Anyone familiar with the art may modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by a person of ordinary skill in the art without departing from the spirit and technical concept disclosed by the present invention shall still be covered by the claims of the present invention.
Claims
1. A preparation process of a sodium hyaluronate composite injection containing lidocaine, characterized in that: The steps include: S1: Preparation of modified sodium hyaluronate The sodium hyaluronate is activated by N-hydroxysuccinimide and 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide, and then cysteamine hydrochloride is added to react and dialyzed to obtain modified sodium hyaluronate; S2: Preparation of lidocaine sustained-release microspheres Lidocaine sustained-release microspheres were prepared by loading lidocaine with poly-L-lactic acid and cooperating with chitosan and poloxamer 407. S3: Preparation of double network structure gel The silk fiber is dialyzed in a lithium bromide solution to prepare a regenerated silk solution, which is then mixed with a modified sodium hyaluronate solution, and horseradish peroxidase and hydrogen peroxide are added to obtain a double network structure gel after incubation. S4: Preparation of composite microgel injection The double network structure gel is immersed in a phosphate buffer solution to obtain a block hydrogel. The block hydrogel, propylene glycol, tripeptide-1, phytosphingosine and lecithin are mixed and homogenized, and then a composite microgel is prepared by a liquid nitrogen quick freezing-crushing method. The composite microgel is dispersed in a physiological buffer solution and lidocaine sustained-release microspheres are added to obtain a composite microgel injection.
2. The preparation process of a sodium hyaluronate composite injection containing lidocaine according to claim 1, characterized in that: Step S1: Preparation of modified sodium hyaluronate, specifically comprising the following steps: S1.1: Dissolve 4-5 parts by weight of sodium hyaluronate powder in 800-1000 parts by weight of deionized water, then add 2-3 parts by weight of N-hydroxysuccinimide and 5-7 parts by weight of 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide in sequence, mix well, adjust the pH to 4-5 with 1.0-1.2 mol / L hydrogen chloride solution, activate at room temperature for 2-3 hours, and obtain an activated solution; S1.2: Add 3-4 parts by weight of cysteamine hydrochloride to the activation solution, then adjust the pH to 4-5 with 1.0-1.2 mol / L sodium hydroxide solution, and react at 23-25° C. in the dark for 20-24 hours to obtain a reactant; S1.3: Transfer the reactants to a dialysis bag and dialyze with deionized water at a pH of 3.5-4 at 23-25°C in the dark for 3-4 days. Then freeze-dry the dialyzed solution to obtain a modified sodium hyaluronate solid, and store it in a refrigerator at 4-5°C for later use.
3. The preparation process of a lidocaine-containing sodium hyaluronate composite injection according to claim 2, characterized in that: Step S2: Preparation of lidocaine sustained-release microspheres, specifically comprising the following steps: S2.1: chitosan and poloxamer 407 are mixed, 1-2 wt% acetic acid is added, the mixture is evenly mixed, and after dissolution, an in-situ gel solution is obtained, and 1-2 parts by weight of lidocaine hydrochloride is added to 10-15 parts by weight of the in-situ gel solution to obtain a mixed solution; S2.2: dissolving 0.25-0.5 parts by weight of poly-L-lactic acid in 2-3 parts by weight of dichloromethane to obtain an oil phase after complete dissolution, adding 0.2-0.3 parts by weight of the mixed solution to the oil phase, and mixing for 1-2 minutes under ice bath conditions at 470-500W ultrasonic assistance to obtain a primary emulsion; S2.3: adding the primary emulsion to 5-8 parts by weight of a 1-2% (w / v) polyvinyl alcohol solution, stirring for 1-2 min at 3400-3500 rpm using a high-speed disperser to obtain a double emulsion, adding the double emulsion to 60-80 parts by weight of a 0.2-0.5% (w / v) polyvinyl alcohol solution, and magnetically stirring at 37-38° C. for 4-5 h to obtain a solidified microsphere solution; S2.4: Centrifuge the solidified microsphere solution at 3500-4000 rpm for 10-12 min, and then wash the precipitate with distilled water 2-3 times to obtain lidocaine sustained-release microspheres.
4. The preparation process of a sodium hyaluronate composite injection containing lidocaine according to claim 3, characterized in that: Step S3: Preparation of the double network structure gel, specifically comprising the following steps: S3.1: 10-20 parts by weight of silk fibroin are placed in 100-200 parts by weight of a 9-10 mol / L lithium bromide solution, stirred and dissolved at 60-62°C for 60-70 min, cooled and placed in a dialysis bag, dialyzed with deionized water for 2-3 days, filtered with absorbent cotton, and centrifuged at 10000-11000 rpm for 5-10 min to obtain a regenerated silk fibroin solution; S3.2: dissolving the modified sodium hyaluronate solid in deionized water to form a modified sodium hyaluronate solution with a mass fraction of 1-2%, then adjusting the pH to 7.4-7.6 with a sodium hydroxide solution, and then adding an equal mass of the regenerated silk fibroin solution and mixing in an ice bath to obtain a mixed solution; S3.3: Add horseradish peroxidase to the mixed solution, then add hydrogen peroxide, stir evenly, place in a biochemical incubator and incubate at 37-38°C for 3-5 hours to obtain a double network structure gel.
5. The preparation process of a sodium hyaluronate composite injection containing lidocaine according to claim 4, characterized in that: Step S4: Preparation of the composite microgel injection, specifically comprising the following steps: S4.1: Soaking the double network structure gel in a 0.01-0.02 mol / L phosphate buffer solution for 3-4 days to obtain a block hydrogel; S4.2: Add 10-20 parts by weight of block hydrogel, 0.2-0.3 parts by weight of propylene glycol and 1-2 parts by weight of tripeptide-1 to 50-80 parts by weight of pure water, and heat in a water bath at 45-48° C. to dissolve to obtain a mixed solution; S4.3: Add 1-2 parts by weight of phytosphingosine to 2-3 parts by weight of lecithin, heat in a water bath at 45-48°C to dissolve, add to the mixture, perform ultrasonic dispersion for 10-20 minutes, and homogenize with a microfluidizer to obtain a mixed emulsified gel solution; S4.4: The mixed emulsified gel solution was placed in liquid nitrogen for quick freezing for 5-8 minutes, then placed in a mortar, crushed with a pestle and repeatedly ground, and sieved with 400-500 μm and 300-400 μm stainless steel sieves in turn to obtain a composite microgel of 300-500 μm; S4.5: The composite microgel is uniformly dispersed in 30-50 parts by weight of physiological buffer, and then 2-3 parts by weight of lidocaine sustained-release microspheres are added, ultrasonically assisted with oscillation for 10-20 minutes, and vacuum-packed after sterilization to obtain a composite microgel injection.
6. The preparation process of a lidocaine-containing sodium hyaluronate composite injection according to claim 3, characterized in that: The concentration of chitosan in the mixed solution of step S2.1 is 3.5-4%.
7. The preparation process of a lidocaine-containing sodium hyaluronate composite injection according to claim 3, characterized in that: The concentration of poloxamer 407 in the mixed solution of step S2.1 is 2.5-3%.
8. The process for preparing a lidocaine-containing sodium hyaluronate composite injection according to claim 4, characterized in that: The concentration of horseradish peroxidase in the mixed solution of step S3.3 is 10-12U / mL.
9. The process for preparing a lidocaine-containing sodium hyaluronate composite injection according to claim 4, characterized in that: The concentration of hydrogen peroxide in the mixed solution in step S3.3 is 3-4 mmol / L.
10. A sodium hyaluronate composite injection containing lidocaine, characterized in that: The hyaluronic acid compound injection is prepared by the preparation process of a lidocaine-containing sodium hyaluronate composite injection according to any one of claims 1 to 9.
Citation Information
Patent Citations
Cysteamine modified sulfhydryl hyaluronic acid couplet, preparation and application thereof
CN101367884A
Pramipexole sustained-release preparation for injection and preparation method thereof
CN108685858A
Preparation method of composite bone morphogenetic protein bionic bone repair material
CN114392394A
Device for crushing freeze-dried decellularized biological tissue gel
CN217856496U
